



## AusIndustry Grants AHI Extension for 2024 R&D Claim Submission

**Advanced Health Intelligence Ltd (ASX: AHI) (AHI or the Company)** AHI is pleased to advise shareholders that it has been granted an extension by AusIndustry to finalise its FY2024 R&D reimbursement submission. The Company anticipates receiving approximately AUD \$1.1 million.

This 31-day extension allows AHI to lodge its final submission by **31 July 2025**, providing the additional time necessary to complete the supporting documentation while managing ongoing operational priorities.

AHI has successfully received annual R&D reimbursements since **2017**, consistently demonstrating its eligibility and commitment to advancing innovation in the health technology sector. This long-standing support from the Australian Government underscores the quality and integrity of AHI's research and development programs.

Notably, in 2023, AHI was approved to include **international R&D expenditures** as part of its claim, recognising the Company's global innovation remit and ongoing investment in expanding its IP portfolio. The 2024 submission represents the second year AHI will include eligible overseas R&D activities. The administrative complexity of this broader claim is a key reason for requesting and securing the extension.

Upon completion of the submission and review process, AHI expects to receive a reimbursement of approximately **AUD \$1.1 million**. These funds will be directed toward general operations and support the Company through a critical phase of its commercial expansion.

### Key Highlights

#### **1. Consistent Reimbursement Record Since 2017**

AHI has maintained a favourable outcome in its R&D reimbursements for seven consecutive years, reinforcing the integrity of its development programs.

#### **2. Global Innovation Footprint**

The Company's expansion into international R&D reflects its growing global presence and supports the development of its proprietary digital health technologies.

#### **3. Expanding Patent Portfolio**

AHI's growing suite of patents—both granted and pending—continues to drive value and strengthens its eligibility under the RDTI scheme.

#### **4. Government Recognition of Technological Leadership**

AHI's endorsement by AusIndustry supports its position as a leading Australian med-tech innovator, contributing to national advancements in digital health.

#### **5. R&D Advance Facility Underway**

In parallel with its RDTI claim, AHI intends to apply for an **R&D Advance Facility** totalling **AUD \$750,000**. This facility, to be arranged through a specialist financier, will provide upfront, non-dilutive funding against expected future reimbursement.

#### **6. Strengthened Cash Flow Position**

Combined, the anticipated reimbursement and advance facility will provide AHI with up to **AUD \$1,850,000** in non-dilutive capital to support operational execution during the second half of 2025.

#### **Vlado Bosanac, Founder and Head of Strategy for AHI, said :**

"The extension granted by AusIndustry underscores AHI's longstanding commitment to innovation and the strength of our R&D programs. Over the past seven consecutive years to 2023, AHI has consistently secured substantial reimbursements under the RDTI scheme. This continued recognition reflects both the quality of our development work and our alignment with national innovation priorities.



Our expanding global footprint, deepening patent portfolio, and proven track record within the med-tech sector continue to position AHI as a leader in digital health. With the FY2024 submission now extended to 31 July 2025, we can ensure the full inclusion of eligible international activities under our approved overseas R&D status, which has become an increasingly valuable component of our claims since 2023.

In parallel, we are advancing an R&D Advanced Facility application for AUD \$750,000. Combined with the expected FY2024 reimbursement, this will provide up to AUD \$AUD1,850,000 in non-dilutive capital, supporting AHI's operational execution through the second half of 2025.

These developments form part of AHI's broader strategic and financial framework to drive long-term value creation and global commercial success."

The Chairman and the CEO of Advanced Health Intelligence Ltd have approved this release.

For more information, contact:

**Vlado Bosanac**  
**Founder/Head of Strategy**  
**Advanced Health Intelligence Limited**  
**E: [admin@ahi.tech](mailto:admin@ahi.tech)**

**Simon Durack**  
**Chief Finance Officer**  
**Advanced Health Intelligence Limited**  
**E: [admin@ahi.tech](mailto:admin@ahi.tech)**

For more information, please visit: [www.ahi.tech](http://www.ahi.tech)

### **About Advanced Health Intelligence Ltd**

AHI offers cutting-edge, smartphone-based health risk identification solutions that enable individuals to run their own comprehensive health assessments and risk stratification.

Utilising smartphone sensor technology, individuals can efficiently conduct a single scan or a series of scans to identify established risk markers for various health conditions. The resulting data can then be shared with healthcare providers, insurers, employers, and government agencies, facilitating timely triage and appropriate care pathway allocation.

AHI's scientific research capability is dedicated to the development of advanced data capture techniques, optimising data input signal quality and continuous enhancement and validation of AHI's solutions through rigorous scientific processes. AHI has assembled a team of experts in machine learning, artificial intelligence, biomathematical modelling and systems biology, computer vision, clinical expertise, and medically trained data scientists to develop and deploy these cutting-edge risk assessment tools.

Over the past decade, AHI has been at the forefront of health-tech innovation, pioneering the use of smartphones in digital-first health care. Our journey began with the groundbreaking development of the world's first on-device body dimensioning capability.

Since then, we have continued to evolve and adapt our solutions to meet the dynamic needs of health systems players dedicated to delivering high-quality patient care and early detection of escalating health conditions. AHI's patented technology has enabled us to push the boundaries of early detection through digital health care, offering a suite of modular solutions that are transforming the industry and offering earlier intervention opportunities.

Our comprehensive solutions encompass:

- Anthropometric and body composition analysis to identify obesity-related comorbidities, including diabetes risk stratification.
- Predictive modelling of blood biomarkers (including HbA1C, HDL-C, LDL-C), and 10-year cardiovascular risk estimation.

- Facial photoplethysmography to assess vital signs non-invasively and provide risk stratification for cardiovascular disease.
- Device-derived dermatological image analysis for identifying over 588 skin conditions across 134 categories, including melanoma detection.
- Atrial Fibrillation technology enables the detection of Atrial Fibrillation using a mobile device. This allows for early identification and monitoring of this common heart condition through a simple, non-invasive, and user-friendly smartphone-based solution.

AHI has developed digital biomarker-driven triage solutions that use only a smartphone or web browser. These solutions enable the identification of health risks across populations and can inform the direction of individuals to appropriate care pathways for proactive health management. The technology provides cost-effective health risk assessment access to billions of smartphone users worldwide, empowering these individuals to take charge of their health journey and improving health outcomes globally.